Related Experiment Videos
Fotemustine: an overview of its clinical activity in disseminated malignant melanoma
D Khayat1, M F Avril, B Gerard
1Hôpital Pitié Salpétrière, Service d'Oncologie Médicale, Paris, France.
Abstract:
Fotemustine is a new chloronitrosourea which is active against disseminated malignant melanoma (DMM), and especially against cerebral metastases (CM). This efficacy has been widely demonstrated through many phase II studies. A multicentre trial of monotherapy was undertaken in 153 evaluable French patients. A response rate (RR) of 24.2% (25.0% RR in CM; 31.8% in non-visceral metastases (NVM) was obtained. Three other phase II studies confirmed these results with respective objective RR of 16.7%, 20.0% and 47.0% and RR in CM of 8.3%, 14.3% and 60.0%. Fotemustine has also been used in combination with dacarbazine (DTIC), in patients with DMM. The RR among 103 patients was 27.2% (26.3% in CM, 37.5% in NVM), confirming the activity of fotemustine. The two drugs have also been administered sequentially, in order to exploit their synergism in interfering with the O6 alkyltransferase. Impressive RR have been achieved, especially in patients with visceral metastases (VM) but at the expense of a pulmonary toxicity that does not arise with other treatment schedules and which precludes its use outside of strictly conducted clinical trials.
Insights
Fotemustine demonstrates significant efficacy in treating disseminated malignant melanoma, particularly for cerebral metastases. This new chloronitrosourea offers a promising therapeutic option for melanoma patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Disseminated malignant melanoma (DMM) presents significant treatment challenges, especially with cerebral metastases (CM).
- Chloronitrosoureas represent a class of chemotherapeutic agents with potential activity against melanoma.
Purpose of the Study:
- To evaluate the efficacy and response rates of fotemustine as a monotherapy and in combination for disseminated malignant melanoma.
- To assess the activity of fotemustine specifically in patients with cerebral and non-visceral metastases.
Main Methods:
- A multicenter trial involving 153 evaluable French patients treated with fotemustine monotherapy.
- Analysis of data from three additional phase II studies and a combination study with dacarbazine (DTIC).
- Evaluation of sequential administration of fotemustine and dacarbazine to exploit O6 alkyltransferase interference.
Main Results:
- Fotemustine monotherapy achieved an overall response rate (RR) of 24.2%, with 25.0% RR in CM and 31.8% in non-visceral metastases (NVM).
- Other phase II studies reported objective RRs ranging from 16.7% to 47.0%, with CM RRs from 8.3% to 60.0%.
- Combination therapy with DTIC yielded a 27.2% RR in DMM patients, including 26.3% in CM and 37.5% in NVM.
Conclusions:
- Fotemustine exhibits significant activity against disseminated malignant melanoma, including challenging cerebral metastases.
- Combination and sequential therapies with dacarbazine show potential but require careful monitoring due to pulmonary toxicity concerns.
- Fotemustine is a viable therapeutic option for DMM, warranting further investigation in controlled clinical settings.